SCHEMBL31516782

SCHEMBL31516782

COc1ccc(C)cc1S(=O)(=O)NC(=O)c1ccc(Cn2cccn2)c(OC)n1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 15/20 0.49
▸ KAT6A Q92794 15/20 0.49
▸ KAT6B Q8WYB5 10/20 0.49
▸ KAT5 Q92993 8/20 0.49
▸ KAT8 Q9H7Z6 8/20 0.49
▸ TSHR P16473 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ ALPL P05186 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172586 0.90 KAT7 (0.52) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172521 0.90 ALPL (0.43) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516712 0.89 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516665 0.89 KAT7 (0.49) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516894 0.89 KAT7 (0.40) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172620 0.88 KAT7 (0.41) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516648 0.88 ALPL (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516638 0.88 KAT7 (0.40) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516693 0.88 KAT7 (0.40) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516681 0.87 KAT7 (0.42) KAT7KAT6AKAT6BKAT5KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885KAT6B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback